These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 21232195)

  • 1. [Acute typhlitis associated with taxane-based chemotherapy].
    Gagliano E; Tonante A; Taranto F; Mamo M; Sturniolo G; Colonese F; Sturniolo G
    G Chir; 2010; 31(11-12):514-7. PubMed ID: 21232195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Re: Lymphopenia associated with adjuvant anthracycline/taxane regimens.
    Cadoo K; Lowery M; McCaffrey J
    Clin Breast Cancer; 2009 Nov; 9(4):262. PubMed ID: 19933084
    [No Abstract]   [Full Text] [Related]  

  • 3. [Management of anthracycline and taxane therapy-induced symptoms for the patients with breast cancer].
    Fukada I; Ito Y
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():548-52. PubMed ID: 25831820
    [No Abstract]   [Full Text] [Related]  

  • 4. Taxane effect in a bladder washing.
    Dustin SM; Jeffus SK; Stelow EB
    Diagn Cytopathol; 2015 Jan; 43(1):32-3. PubMed ID: 24644138
    [No Abstract]   [Full Text] [Related]  

  • 5. Taxane-induced scleroderma.
    Itoh M; Yanaba K; Kobayashi T; Nakagawa H
    Br J Dermatol; 2007 Feb; 156(2):363-7. PubMed ID: 17223879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GM1 for taxane-induced neuropathy in breast cancer.
    Das M
    Lancet Oncol; 2019 Jul; 20(7):e348. PubMed ID: 31130320
    [No Abstract]   [Full Text] [Related]  

  • 7. No flow pattern on indocyanine green lymphography in breast cancer patients undergoing taxane-based chemotherapy.
    Tokumoto H; Akita S; Nakamura R; Yamamoto N; Kubota Y; Mitsukawa N
    J Plast Reconstr Aesthet Surg; 2020 Aug; 73(8):1575-1592. PubMed ID: 32269010
    [No Abstract]   [Full Text] [Related]  

  • 8. Body Composition, Adherence to Anthracycline and Taxane-Based Chemotherapy, and Survival After Nonmetastatic Breast Cancer.
    Cespedes Feliciano EM; Chen WY; Lee V; Albers KB; Prado CM; Alexeeff S; Xiao J; Shachar SS; Caan BJ
    JAMA Oncol; 2020 Feb; 6(2):264-270. PubMed ID: 31804676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug evaluation: Bay-59-8862.
    Eckstein JW
    IDrugs; 2004 Jun; 7(6):575-81. PubMed ID: 15197663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case of taxane-induced scleroderma: a different expression profile of Fli1 proteins in dermal fibroblasts and microvascular endothelial cells compared with systemic sclerosis.
    Takahashi T; Asano Y; Ichimura Y; Taniguchi T; Kogure A; Tamaki Z; Takekoshi T; Sugaya M; Sato S
    Br J Dermatol; 2011 Jun; 164(6):1393-5. PubMed ID: 21299546
    [No Abstract]   [Full Text] [Related]  

  • 11. Prolonged disease control in a patient with anthracycline- and taxane-resistant breast cancer.
    Castaneda CA; Gómez HL
    Clin Breast Cancer; 2009 Nov; 9(4):E1-3. PubMed ID: 19933071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging nontaxane therapies for metastatic breast cancer.
    O'Regan R
    Clin Adv Hematol Oncol; 2012 Mar; 10(3):187-9. PubMed ID: 22402428
    [No Abstract]   [Full Text] [Related]  

  • 13. Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy.
    Blum JL; Dees EC; Vukelja SJ; Amare M; Gill DP; McMahon RT; Ilegbodu D; Asmar L; O'Shaughnessy JA
    Clin Breast Cancer; 2007 Feb; 7(6):465-70. PubMed ID: 17386123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive impairment with significant brain parenchymal volume loss following standard adjuvant chemotherapy in a patient with breast cancer.
    Swayampakula AK; Alkhouri N; Haut MW; Abraham J
    Clin Adv Hematol Oncol; 2007 Dec; 5(12):985-7; discussion 987-8. PubMed ID: 18277960
    [No Abstract]   [Full Text] [Related]  

  • 15. [High-risk situation - which is the best chemotherapy?].
    von Minckwitz G
    Gynakol Geburtshilfliche Rundsch; 2008; 48(3):118-29. PubMed ID: 18566528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are pharmacogenomic biomarkers an effective tool to predict taxane toxicity and outcome in breast cancer patients? Literature review.
    De Iuliis F; Salerno G; Taglieri L; Scarpa S
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):679-90. PubMed ID: 26198313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients.
    Monfort SM; Pan X; Patrick R; Ramaswamy B; Wesolowski R; Naughton MJ; Loprinzi CL; Chaudhari AMW; Lustberg MB
    Breast Cancer Res Treat; 2017 Jul; 164(1):69-77. PubMed ID: 28374323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular risk profile of patients with HER2/neu-positive breast cancer treated with anthracycline-taxane-containing adjuvant chemotherapy and/or trastuzumab.
    Jones LW; Haykowsky M; Peddle CJ; Joy AA; Pituskin EN; Tkachuk LM; Courneya KS; Slamon DJ; Mackey JR
    Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):1026-31. PubMed ID: 17507633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Possible mechanisms behind taxane-anthracycline sequencing.
    Sahin I; Ararat E; Altundag K
    Lancet Oncol; 2010 Jun; 11(6):514-5. PubMed ID: 20522380
    [No Abstract]   [Full Text] [Related]  

  • 20. Hyperthermic intraperitoneal chemotherapy after extensive cytoreductive surgery in patients with primary advanced epithelial ovarian cancer: interim analysis of a phase II study.
    Lim MC; Kang S; Choi J; Song YJ; Park S; Seo SS; Park SY
    Ann Surg Oncol; 2009 Apr; 16(4):993-1000. PubMed ID: 19169758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.